Tóm tắt
Introduction: High-risk neuroblastoma is a childhood malignancy with a poor prognosis. Gradual improvements in survival have correlated with therapeutic intensity, and the ability to harvest, process, and store autologous hematopoietic stem cells has allowed for dose intensification beyond marrow tolerance.
Case: We report two cases diagnosed with high-risk neuroblastoma. The first case involved a 5-year-old male with a large heterogeneous tumor in his left adrenal gland and metastasis in the bone marrow and brain. The second case was a 5-year-old female with a localized tumor in her right kidney and NMYC positive. Both cases were treated with the SIOPEN protocol, starting with 8 courses of RAPID COJECT. After partial response, stem cells were collected, followed by primary tumor resection, high-dose chemotherapy with autologous stem cell rescue, radiation, and retinoic acid treatment.
Conclusion: This report is the initial documentation of autologous stem cell transplant for high-risk neuroblastoma. Despite involving only two patients, the results indicated that stem cell transplant was safe and effective. We aim to implement this treatment for more cases of high-risk neuroblastoma and report further findings with a larger cohort.
Tài liệu tham khảo
Trahair TN, Vowels MR, Johnston K, Cohn RJ, Russell SJ, Neville KA, et al. Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant. 2007; 40: 741 - 6.
Lau SCD, Unni MNM, Teh KH, Aziz MA, Muda Z, Thomas SA, et al. Autologous stem cell transplantation following high-dose chemotherapy in children with high-risk neuroblastoma: Practicality in resource-limited countries. Pediatr Blood Cancer. 2020; 67: e28176.
Elzembely MM, Park JR, Riad KF, Sayed HA, Pinto N, Carpenter PA, et al. Acute complications after high-dose chemotherapy and stem-cell rescue in pediatric patients with high-risk neuroblastoma treated in countries with different resources. J Glob Oncol. 2018; 4: 1 - 12.
Fish JD, Grupp SA. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant. 2008; 41: 159 - 65.
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999; 341: 1165 - 73.
Soni S, Pai V, Gross TG, Ranalli M. Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children’s Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution. Pediatr Transplant. 2014; 18: 217 - 20.
Yalcin B, Kremer LC, Caron HN, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev. 2013: CD006301.
Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, et al. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015; 62: 1305 - 16.
Peinemann F, van Dalen EC, Enk H, Berthold F. Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2017; 8: CD010685.
Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF, et al. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant. 2003; 31: 861 - 4.
| Đã xuất bản | 20-06-2020 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Số 62 (2020) | |
| Phân mục | Báo cáo trường hợp | |
| DOI | 10.38103/jcmhch.2020.62.16 | |
| Từ khóa |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2020 Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế